Literature DB >> 16719868

Pheomelanin and eumelanin in human skin determined by high-performance liquid chromatography and its relation to in vivo reflectance measurements.

Brian Kongshoj1, Ari Thorleifsson, Hans Christian Wulf.   

Abstract

BACKGROUND/
PURPOSE: Clinical experience has shown that red haired, fair-skinned people have an increased frequency of skin cancer and in addition a relatively high content of pheomelanin and low content of eumelanin in their skin. Of these, eumelanin is presumed photoprotective, and pheomelanin phototoxic. Thus, a fast, easy, and non-invasive method for determining skin content of eumelanin and pheomelanin was sought.
METHODS: Skin reflectance measurements using a UV-Optimize apparatus were performed before taking suction blisters of the same skin area. Each skin sample was freeze dried and submitted to alkaline hydrogen peroxide degradation. Two eumelanin degradation compounds:Pyrrole-2,3-dicarboxylic acid (PDCA) and pyrrole-2,3,5-tricarboxylic acid (PTCA), and two pheomelanin degradation compounds: Thiazole-4,5-dicarboxylic acid (TDCA) and 1,3-thiazole-2,4,5-tricarboxylic acid (TTCA) were determined in a single chromatographic analysis. Each degradation compound was correlated to reflectance measurements of red (660 nm), green (555 nm), and blue (488 nm) light and additionally correlated to the pigmentation % and redness % given by UV-Optimize.
RESULTS: Neither of the investigated parameters were significantly correlated to either PDCA or TTCA. Contrarily, a highly significant correlation was found for the eumelanin marker, PTCA (r2=0.79, P<0.0001). The pheomelanin marker, TDCA, was likewise found to be significantly correlated (r2=0.43, P<0.0001).
CONCLUSION: Based on the coefficients of determination it was concluded that in vivo spectrophotometric reflectance measurements of human skin were highly useful for determining the eumelanin content of skin and to classify the pheomelanin content of skin non-invasively. This may be used individually and in population-based studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719868     DOI: 10.1111/j.1600-0781.2006.00215.x

Source DB:  PubMed          Journal:  Photodermatol Photoimmunol Photomed        ISSN: 0905-4383            Impact factor:   3.135


  5 in total

1.  Sun and ski holidays improve vitamin D status, but are associated with high levels of DNA damage.

Authors:  Bibi Petersen; Hans C Wulf; Margarita Triguero-Mas; Peter A Philipsen; Elisabeth Thieden; Peter Olsen; Jakob Heydenreich; Payam Dadvand; Xavier Basagaña; Tove S Liljendahl; Graham I Harrison; Dan Segerbäck; Alois W Schmalwieser; Antony R Young; Mark J Nieuwenhuijsen
Journal:  J Invest Dermatol       Date:  2014-05-20       Impact factor: 8.551

2.  Skin pigmentation and genetic variants in an admixed Brazilian population of primarily European ancestry.

Authors:  Jeppe D Andersen; Olivia S Meyer; Filipa Simão; Juliana Jannuzzi; Elizeu Carvalho; Mikkel M Andersen; Vania Pereira; Claus Børsting; Niels Morling; Leonor Gusmão
Journal:  Int J Legal Med       Date:  2020-05-09       Impact factor: 2.686

3.  Analysis of Skin Pigmentation and Genetic Ancestry in Three Subpopulations from Pakistan: Punjabi, Pashtun, and Baloch.

Authors:  Muhammad Adnan Shan; Olivia Strunge Meyer; Mie Refn; Niels Morling; Jeppe Dyrberg Andersen; Claus Børsting
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

4.  Pigmentary Markers in Danes--Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome.

Authors:  Peter Johansen; Jeppe Dyrberg Andersen; Linnea Nørgård Madsen; Henrik Ullum; Martin Glud; Claus Børsting; Robert Gniadecki; Niels Morling
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

5.  Importance of nonsynonymous OCA2 variants in human eye color prediction.

Authors:  Jeppe D Andersen; Carlotta Pietroni; Peter Johansen; Mikkel M Andersen; Vania Pereira; Claus Børsting; Niels Morling
Journal:  Mol Genet Genomic Med       Date:  2016-03-11       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.